Sean Glenn

Biography:

I received a Bachelor’s of Science in Biology from the State University of New York at Buffalo where I studied the RIP function in Neurospora crassa which is a duplication and mutation event localized to the premeiotic cells of the life cycle. I then went on to earn a Master’s of Science from the University at Buffalo focusing on transcriptional regulation of genes responsible for vascular development.

Furthermore, I received a PhD in Molecular and Cellular Biology from the Roswell Park Comprehensive Cancer Center Division of the University of Buffalo where, in the laboratory of Dr. Kenneth W. Gross, I developed a mouse model that mimics human metastatic pancreatic neuroendocrine carcinoma. This model, coupled with NGS technology, is a powerful tool for studying the cooperating mutations responsible for the evolution of metastatic disease including the identification and the role circulating tumor cells play in the progression of this process. This model also offers great promise for studying the pharmaceutical intervention of the metastatic phenotype.

With an interest in advanced genomic technologies and tumor mutation profiling I began my training in Molecular Pathology receiving a Certificate of Qualification from the NYS DOH. This clinical accreditation affords me the opportunity to act as director of the clinical Advanced Molecular Diagnostic Laboratory as well as submit cutting-edge clinical assays to the NYS CLEP program for use as diagnostic, prognostic and therapeutic testing for our patients. Leveraging my experience using stare-of-the-art genomics technologies along with my clinical responsibilities as lab director and Vice-Chair I drive strategic partnerships and commercialization of intellectual property developed at Roswell Park for use throughout the country and world, maintain Roswell on the forefront of innovation in the field of oncology.